REPLY
- PMID: 32598515
- DOI: 10.1002/hep.31438
REPLY
Comment on
-
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.Hepatology. 2021 Feb;73(2):661-673. doi: 10.1002/hep.31289. Epub 2020 Nov 2. Hepatology. 2021. PMID: 32324905
-
Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.Hepatology. 2021 Jan;73(1):466. doi: 10.1002/hep.31439. Epub 2020 Dec 7. Hepatology. 2021. PMID: 32602169 No abstract available.
References
-
- Choi J, Jo C, Lim YS. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. Hepatology 2020 Apr 23. https://doi.org/10.1002/hep.31289. [Epub ahead of print]
-
- Zhang M, Wang D, Liu H, Li H. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agent Cancer 2018;13:19.
-
- Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017;66:1444-1453.
-
- Choi WM, Choi J, Lim YS. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020 May 11;S1542-3565(20)30642-X. https://doi.org/10.1016/j.cgh.2020.05.008. [Epub ahead of print]
-
- Zhang Z, Zhou Y, Yang J, Hu K, Huang Y. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer 2019;19:511.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
